Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial

JAMA. 2003 Nov 5;290(17):2284-91. doi: 10.1001/jama.290.17.2284.


Context: The development of contrast-induced nephropathy in patients undergoing invasive cardiac procedures is associated with a marked increase in cardiovascular morbidity and mortality. Fenoldopam mesylate, a specific agonist of the dopamine-1 receptor, preserves renal blood flow after iodinated contrast administration and has shown promise in ameliorating contrast nephropathy in previous observational and small randomized trials.

Objective: To examine the efficacy of fenoldopam mesylate in preventing contrast nephropathy after invasive cardiovascular procedures.

Design: Prospective, placebo-controlled, double-blind, multicenter randomized trial with serial serum creatinine levels measured at a central biochemistry laboratory (at baseline and 1, 24, 48, and 72 to 96 hours after study drug administration) and 30-day clinical follow-up.

Patients and setting: Between March 2001 and July 2002, 315 patients with creatinine clearance less than 60 mL/min (1.00 mL/s) at 28 centers in the United States were randomized to receive fenoldopam mesylate (n = 157) or placebo (n = 158).

Interventions: Patients were hydrated and randomized to receive intravenous fenoldopam (0.05 microg/kg/min titrated to 0.10 microg/kg/min) vs matching placebo, starting 1 hour prior to angiography and continuing for 12 hours.

Main outcome measure: Contrast-induced nephropathy, defined as an increase of 25% or more in serum creatinine level within 96 hours postprocedure.

Results: Mean (SD) patient age was 70 (11) years, and 49% had diabetes mellitus. Mean (SD) baseline creatinine clearance was 29.0 (10.0) mL/min (0.48 [0.16] mL/s) (range, 7.5-56.8 mL/min [0.12-0.94 mL/s]), and 157 (108) mL of contrast was administered during the procedures. The primary end point of contrast-induced nephropathy occurred in 33.6% of patients assigned to receive fenoldopam vs 30.1% assigned to receive placebo (relative risk, 1.11; 95% confidence interval, 0.79-1.57; P =.61). There were no significant differences in the 30-day rates of death (2.0% vs 3.8%, P =.50), dialysis (2.6% vs 1.9%, P =.72), or rehospitalization (17.6% vs 19.9%, P =.66) in fenoldopam vs placebo randomized patients, respectively.

Conclusion: The selective dopamine-1 agonist fenoldopam mesylate does not prevent further renal function deterioration after contrast administration in patients with chronic renal insufficiency.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Angiography*
  • Angioplasty, Balloon, Coronary
  • Contrast Media / adverse effects*
  • Creatinine / blood
  • Dopamine Agonists / therapeutic use*
  • Double-Blind Method
  • Female
  • Fenoldopam / therapeutic use*
  • Heart Diseases / complications*
  • Heart Diseases / diagnosis
  • Heart Diseases / therapy
  • Humans
  • Iodine Compounds / adverse effects*
  • Kidney Diseases / chemically induced*
  • Kidney Diseases / prevention & control*
  • Kidney Failure, Chronic / complications*
  • Male
  • Middle Aged
  • Prospective Studies
  • Vasodilator Agents / therapeutic use*


  • Contrast Media
  • Dopamine Agonists
  • Iodine Compounds
  • Vasodilator Agents
  • Creatinine
  • Fenoldopam